Synonym:
Buprenorphine hydrochloride,
[5α,7α(S)]-17-(Cyclopropylmethyl)-α-(1,1-dimethylethyl)4,5-epoxy-18,19-dihydo-3-hydroxy-6-methoxy-α-methyl-6,14-ethenomorphinan-7-methanol hydrochloride
Properties:
| Related Categories |
Additional Standards,
Analytical Standards,
Analytical/Chromatography,
Chromatography,
Pharmaceutical Secondary Standards,
|
|
grade
|
certified reference material
|
|
|
pharmaceutical secondary standard
|
|
InChI Key
|
UAIXRPCCYXNJMQ-RZIPZOSSSA-N
|
|
packaging
|
pkg of 50 mg
|
|
drug control
|
USDEA Schedule III; regulated under CDSA - not available from Sigma-Aldrich Canada; psicótropo (Spain); Decreto Lei 15/93: Tabela IIC (Portugal)
|
|
pharmacopeia traceability
|
traceable to PhEur Y0001109
|
|
|
traceable to USP 1078700
|
Description:
Analysis Note
These secondary standards offer multi-traceability to the USP, EP and BP primary standards, where they are available.
General description
Certified pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards
Other Notes
This product was designed, produced and verified for accuracy and stability in accordance with ISO/IEC 17025:2005 (AClass Cert AT-1467), ISO GUIDES 34:2009 (AClass Cert AR-1470).
Biochem/physiol Actions
Full agonist at ORL1 receptors, antagonist or partial agonist at μ, κ, and δ opioid receptors.
Footnote
To see an example of a Certificate of Analysis for this material enter LRAA7438 in the Documents slot below. This is an example certificate only and may not be the lot that you receive.
Safety:
Symbol


GHS07, GHS08
Hazard statements
H302-H361
Precautionary statements
P201-P301 + P312 + P330-P308 + P313
RIDADR
NONH for all modes of transport